Lower extremity artery disease in patients with type 2 diabetes
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Among all peripheral arterial diseases, lower extremity arterial disease is a serious condition in subjects with type 2 diabetes mellitus, associated with important disability, cardiovascular risk, and socio-economic burden. Patients with both conditions generally display poorer prognosis of affected limbs compared with non-diabetic subjects, leading to increased rates of adverse limb events including amputations. Nonetheless, awareness on lower extremity arterial disease remains somehow suboptimal in the diabetic population, partly related to an atypical clinical presentation in several cases. A regular and appropriate screening for lower extremity arterial disease in patients suffering from type 2 diabetes mellitus is therefore recommended. Affected subjects should receive optimal medical treatment including careful management of the different cardiovascular risk factors through a healthy lifestyle, a regular and structured physical activity, the administration of lipid-lowering, antidiabetic drugs, and (when indicated) antihypertensive and antithrombotic drugs. This review aims to outline current evidence about lower extremity arterial disease in patients with type 2 diabetes mellitus, in order to elucidate its epidemiology, pathophysiology, screening and diagnosis, and management options.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, patients with microangiopathy are at increased risk of CLTI and major amputation.754,755”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [755]
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 1×
“For the SGLT2 inhibitors, the evidence is modestly stronger for empagliflozin than canagliflozin, which also showed some benefit in terms of CV profile, as compared with placebo.(44)”
Background10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial, for example, found that semaglutide was associated with a reduction of 35% in coronary and peripheral revascularizations, but no specific data were available regarding lower limb proce…”
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503 · cited 12×
“In the European Study Group on Diabetes and the Lower Extremity study, LEAD was present in 49% of subjects with diabetic foot, while one-third of participants had either LEAD or infection.11 Subjects with LEAD and T2DM are also at higher risk of major adverse limb events (MALEs), including lower limb amputation (LLA)…”
InfluentialEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“Furthermore, the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study demonstrated the additional benefits of this drug, in reducing the CV risk as compared with patients treated with statins alone.(49) These effects remained significant also in the subgroup of…”
ResultCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Fowkes, F. G. R., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J. O., McDermott, M. M., Norman, P. E., Sampson, U. K., Williams, L. J., Mensah, G. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61249-0 · Cited by 3,508
Self-citationAboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Self-citation
Research works printed but not linked: 2
- Lane R, 2014, Cochrane Database Syst Rev, 7
- Cosentino F, 2019, Eur Heart J
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citation2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Mazzolai, L., Teixido-Tura, G., Lanzi, S., Boc, V., Bossone, E., Brodmann, M., Bura-Rivière, A., De Backer, J., Deglise, S., Della Corte, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae179 · Cited by 993
Self-citationLi, W., Song, Y., Chen, K., Ying, J., Zheng, Z., Qiao, S., Yang, M., Zhang, M., & Zhang, Y. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050989 · Cited by 76
Adou, C., Magné, J., Gazere, N., Aouida, M., Chastaingt, L., & Aboyans, V. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad381 · Cited by 56
Self-citationCardoso, C. R. L., de Melo, J. V., Santos, T. R. M., Leite, N. C., & Salles, G. F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01249-y · Cited by 44
Metadata
- Authors
- Buso, G., Aboyans, V., & Mazzolai, L.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Inserm (FR)
- Corresponding author
- Mazzolai, Lucia
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-26
- Volume
- 26
- Issue
- 2_suppl
- Pages
- 114-124
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2990130692
- Cited by
- 48
- References
- 60
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 16 · 2023: 8 · 2022: 6 · 2021: 5 · 2020: 2 · 2019: 1
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- European Journal of Preventive Cardiology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lower extremity arterial disease, type 2 diabetes, peripheral arterial disease, diabetic vascular complications, amputation, cardiovascular risk, screening, diagnosis, pathophysiology, optimal medical therapy, physical activity, lipid-lowering therapy, antithrombotic therapy
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Life Style, Mass Screening, Prognosis, Exercise, Thrombolytic Therapy, Peripheral Vascular Diseases, Lower Extremity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lower extremity artery disease in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1177/2047487319880044
- The paper
- Buso, G., Aboyans, V., & Mazzolai, L. (2019). Lower extremity artery disease in patients with type 2 diabetes. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487319880044
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.